comparemela.com

Guillaume Turc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IV Thrombolysis Offers No Benefit for Mild Stroke

Guidelines on Rapid BP Reduction in Stroke Challenged

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

ESO guidelines provide recommendations on intravenous thrombolysis for acute ischemic stroke

ESO guidelines provide recommendations on intravenous thrombolysis for acute ischemic stroke Patients with stroke due to blood clots in brain arteries ( ischaemic stroke ) can be treated with clot-dissolving drugs called thrombolytics . By dissolving blood clots, thrombolytic drugs improve brain blood supply and lead to better recovery. However, thrombolytic drugs may cause bleeding in the brain which can lead to worse disability or death. The most commonly used thrombolytic drug for ischemic stroke is called alteplase. Related Stories The European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke provides forty recommendations on the use of thrombolytic drugs. The module working group, led by Guillaume Turc, William Whiteley and the late Eivind Berge, has written evidence-based recommendations and expert consensus statements covering the topics of early and late time windows, stroke of unknown onset, advanced imaging, alteplase and tenec

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.